Infusion Therapy Market To Reach USD 10.98 Billion By 2027 | Reports and Data
March 11, 2020 11:00 ET
|
Reports and Data
New York, March 11, 2020 (GLOBE NEWSWIRE) -- The Global Infusion therapy market is forecast to reach USD 10.98 Billion by 2027, according to a new report by Reports and Data. Infusion therapy is...
Neuroprosthetics Market To Reach USD 15.8 Billion By 2026 | Reports And Data
January 14, 2020 10:01 ET
|
Reports and Data
New York, Jan. 14, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Neuroprosthetics market was valued at USD 6.1 Billion in 2018 and is expected to reach...
Toronto Innovation Acceleration Partners (TIAP) adds novel KRAS oncology project to its LAB150 portfolio
December 12, 2019 07:00 ET
|
Toronto Innovation Acceleration Partners
Toronto, ON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- The low survival rates of three of the four most lethal cancers in North America - pancreatic, colorectal and lung - are associated with KRAS...
Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data
December 03, 2019 18:00 ET
|
Reports and Data
New York, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Increased focus on drug discovery, accelerated delivery of new treatments for patients, introduction of novel and highly efficient therapies, a variety of...
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market To Reach USD 783 Million By 2026 | Reports And Data
November 18, 2019 10:14 ET
|
Reports and Data
New york, Nov. 18, 2019 (GLOBE NEWSWIRE) -- High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding...
Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma
November 06, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
ONL Therapeutics Announces First Patient Treated in Phase I Study with ONL1204
October 23, 2019 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
Teneobio Licenses Oncology Multispecific Product to Janssen
September 30, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit
September 16, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma
July 15, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...